BR9708287A - Processo para tratar ou prevenir um distúrbio do sistema nervoso central em um ser humano, para eliciar um efeito antiemético em um ser humano e para tratar um estado de doença em um ser humano, composição farmacêutica para tratar de distúrbios do sistema nervoso central em um ser humano, e, forma de dosagem unitária farmacêutica - Google Patents
Processo para tratar ou prevenir um distúrbio do sistema nervoso central em um ser humano, para eliciar um efeito antiemético em um ser humano e para tratar um estado de doença em um ser humano, composição farmacêutica para tratar de distúrbios do sistema nervoso central em um ser humano, e, forma de dosagem unitária farmacêuticaInfo
- Publication number
- BR9708287A BR9708287A BR9708287-2A BR9708287A BR9708287A BR 9708287 A BR9708287 A BR 9708287A BR 9708287 A BR9708287 A BR 9708287A BR 9708287 A BR9708287 A BR 9708287A
- Authority
- BR
- Brazil
- Prior art keywords
- human
- treating
- nervous system
- central nervous
- dosage form
- Prior art date
Links
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title abstract 4
- 238000000034 method Methods 0.000 title abstract 3
- 230000003474 anti-emetic effect Effects 0.000 title abstract 2
- 201000010099 disease Diseases 0.000 title abstract 2
- 239000002552 dosage form Substances 0.000 title abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- 208000015114 central nervous system disease Diseases 0.000 title 2
- 208000012902 Nervous system disease Diseases 0.000 title 1
- 230000002411 adverse Effects 0.000 abstract 2
- 210000003169 central nervous system Anatomy 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- 208000035475 disorder Diseases 0.000 abstract 2
- 239000003814 drug Substances 0.000 abstract 2
- 229940079593 drug Drugs 0.000 abstract 2
- OMLDMGPCWMBPAN-YPMHNXCESA-N norcisapride Chemical compound CO[C@H]1CNCC[C@H]1NC(=O)C1=CC(Cl)=C(N)C=C1OC OMLDMGPCWMBPAN-YPMHNXCESA-N 0.000 abstract 2
- 230000003389 potentiating effect Effects 0.000 abstract 2
- ZDLILMQNLSEPLK-UHFFFAOYSA-N 2-chloro-5-methoxy-n-piperidin-4-ylpyrimidin-4-amine Chemical compound COC1=CN=C(Cl)N=C1NC1CCNCC1 ZDLILMQNLSEPLK-UHFFFAOYSA-N 0.000 abstract 1
- 206010013710 Drug interaction Diseases 0.000 abstract 1
- 239000002111 antiemetic agent Substances 0.000 abstract 1
- 229940125683 antiemetic agent Drugs 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4468—Non condensed piperidines, e.g. piperocaine having a nitrogen directly attached in position 4, e.g. clebopride, fentanyl
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Otolaryngology (AREA)
- Nutrition Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Polysaccharides And Polysaccharide Derivatives (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
"PROCESSOS PARA TRATAR OU PREVENIR UM DISTúRBIO DO SISTEMA NERVOSO CENTRAL EM UM SER HUMANO, PARA ELICIAR UM EFEITO ANTIEMéTICO EM UM SER HUMANO E PARA TRATAR UM ESTADO DE DOENçA EM UM SER HUMANO, COMPOSIçãO FARMACêUTICA PARA TRATAR DE DISTúRBIOS DO SISTEMA NERVOSO CENTRAL EM UM SER HUMANO, E, FORMA DE DOSAGEM UNITáRIA FARMACêUTICA". Composições empregando, e processos utilizando, o (+) isómero de norcisaprida oticamente puro, são apresentados. Este composto foi surpreendentemente observado ser um medicamento potente para o tratamento de distúrbios do sistema nervoso central. O composto, (+) norcisaprida, também tem sido observada ser um agente antiemético potente. Finalmente, o (+) isómero de norcisaprida também evita certos efeitos colaterais adversos e certas interações adversas de medicamentos.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US08/684,753 US5739151A (en) | 1996-07-19 | 1996-07-19 | Method for treating emesis and central nervous system disorders using optically pure (+) norcisapride |
| PCT/US1997/011629 WO1998003173A1 (en) | 1996-07-19 | 1997-07-02 | Methods for treating emesis and central nervous system disorders using optically pure (+) norcisapride |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR9708287A true BR9708287A (pt) | 2000-01-18 |
Family
ID=24749413
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR9708287-2A BR9708287A (pt) | 1996-07-19 | 1997-07-02 | Processo para tratar ou prevenir um distúrbio do sistema nervoso central em um ser humano, para eliciar um efeito antiemético em um ser humano e para tratar um estado de doença em um ser humano, composição farmacêutica para tratar de distúrbios do sistema nervoso central em um ser humano, e, forma de dosagem unitária farmacêutica |
Country Status (25)
| Country | Link |
|---|---|
| US (3) | US5739151A (pt) |
| EP (1) | EP0896539B1 (pt) |
| JP (1) | JP3097697B2 (pt) |
| KR (4) | KR100422492B1 (pt) |
| CN (1) | CN1215992A (pt) |
| AT (1) | ATE197762T1 (pt) |
| AU (1) | AU3592097A (pt) |
| BG (1) | BG63190B1 (pt) |
| BR (1) | BR9708287A (pt) |
| CA (1) | CA2245768C (pt) |
| CZ (1) | CZ293478B6 (pt) |
| DE (1) | DE69703617T2 (pt) |
| DK (1) | DK0896539T3 (pt) |
| ES (1) | ES2152687T3 (pt) |
| GR (1) | GR3035460T3 (pt) |
| HU (1) | HUP9904360A3 (pt) |
| IL (1) | IL125703A0 (pt) |
| IS (1) | IS4820A (pt) |
| NO (2) | NO317178B1 (pt) |
| NZ (1) | NZ331291A (pt) |
| PL (1) | PL189610B1 (pt) |
| PT (1) | PT896539E (pt) |
| SK (1) | SK282673B6 (pt) |
| TR (1) | TR199801816T2 (pt) |
| WO (1) | WO1998003173A1 (pt) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5712293A (en) * | 1995-06-07 | 1998-01-27 | Sepracor, Inc. | Methods for treating gastro-esophageal reflux disease and other disorders associated with the digestive tract using optically pure (-) norcisapride |
| US5739151A (en) * | 1996-07-19 | 1998-04-14 | Sepracor Inc. | Method for treating emesis and central nervous system disorders using optically pure (+) norcisapride |
| US6147093A (en) * | 1996-07-19 | 2000-11-14 | Sepracor Inc. | Methods for treating gastroesophageal reflux disease |
| WO1998016511A1 (en) * | 1996-10-15 | 1998-04-23 | Janssen Pharmaceutica N.V. | Synthesis of cisapride |
| JP3529102B2 (ja) * | 1997-07-11 | 2004-05-24 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノート シヤツプ | ５−ｈｔ３および５−ｈｔ４介在性障害に有用な（＋）−ノルシサプリド |
| TR200103759T2 (tr) * | 1998-06-15 | 2002-06-21 | Sepracor Inc. | Apne, bulimi ve başka bozuklukların tedavi edilmesi için optik açıdan saf (-) norsisapridin kullanımı |
| PT1089733E (pt) | 1998-06-15 | 2005-08-31 | Sepracor Inc | Utilizacao de (+)-norcisaprida optixamente pura para tratamento da sindroma do colon irritavel |
| EP1468685A3 (en) * | 1998-06-15 | 2004-12-15 | Sepracor Inc. | Use of optically pure (+)-norcisapride for treating apnea, bulimia and other disorders |
| EP1464333A3 (en) * | 1998-06-15 | 2004-12-15 | Sepracor Inc. | Use of optically pure (-) norcisapride in the treatment of apnea, bulimia, and other disorders |
| KR100529659B1 (ko) * | 1998-08-21 | 2005-11-21 | 노파르티스 아게 | 5-ｈｔ4 작동제 또는 길항제를 위한 신규한 경구 투여용제제 |
| US6362202B1 (en) * | 1999-03-02 | 2002-03-26 | Sepracor Inc. | Methods and compositions using (−) norcisapride in combination with proton pump inhibitors or H2 receptor antagonists |
| US6353005B1 (en) * | 1999-03-02 | 2002-03-05 | Sepracor, Inc. | Method and compositions using (+) norcisapride in combination with proton pump inhibitors or H2 receptor antagonist |
| US6803387B1 (en) | 1999-03-19 | 2004-10-12 | Abbott Gmbh & Co. Kg | Treatment of neuropathic pain or fibromyalgia |
| US20020013327A1 (en) * | 2000-04-18 | 2002-01-31 | Lee Andrew G. | Compositions and methods for treating female sexual dysfunction |
| EP1321142A1 (en) * | 2001-12-21 | 2003-06-25 | Novartis AG | Solid pharmaceutical composition for oral administration of Tegaserod |
| FR2854072B1 (fr) * | 2003-04-23 | 2006-08-04 | Centre Nat Rech Scient | Vecteur pour administration par voie orale |
| PT2194053E (pt) * | 2004-01-07 | 2013-07-08 | Armetheon Inc | Derivados de metoxipiperidina para utilização no tratamento de distúrbios gastrointestinais e do sistema nervoso central |
| US8138204B2 (en) * | 2004-01-07 | 2012-03-20 | Aryx Therapeutics, Inc. | Stereoisomeric compounds and methods for the treatment of gastrointestinal and central nervous system disorders |
| US8524736B2 (en) | 2004-01-07 | 2013-09-03 | Armetheon, Inc. | Stereoisomeric compounds and methods for the treatment of gastrointestinal and central nervous system disorders |
| US20090170899A1 (en) * | 2004-09-14 | 2009-07-02 | Guy Debonnel | Stimulators of 5-HT4 receptors and uses thereof |
| WO2007028073A2 (en) * | 2005-08-31 | 2007-03-08 | Aryx Therapeutics, Inc. | Synthetic methods and intermediates for stereoisomeric compounds useful for the treatment of gastrointestinal and central nervous system disorders |
| WO2007149929A1 (en) * | 2006-06-23 | 2007-12-27 | Aryx Therapeutics, Inc. | Piperidine derivatives for the treatment of gastrointestinal and cns disorders |
| US20120208892A1 (en) | 2009-10-16 | 2012-08-16 | Epiomed Therapeutics, Inc. | Emesis treatment |
| PL2678332T3 (pl) * | 2011-02-25 | 2016-12-30 | Pochodne diaminopirymidyny i sposoby ich wytwarzania |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5137896A (en) * | 1981-10-01 | 1992-08-11 | Janssen Pharmaceutica N.V. | N-(3-hydroxy-4-piperidinyl)benzamide derivatives |
| US4962115A (en) * | 1981-10-01 | 1990-10-09 | Janssen Pharmaceutica N.V. | Novel N-(3-hydroxy-4-piperidinyl)benzamide derivatives |
| US5057525A (en) * | 1981-10-01 | 1991-10-15 | Janssen Pharmaceutica N.V. | Novel N-(3-hydroxy-4-piperidinyl) benzamide derivatives |
| CA1183847A (en) * | 1981-10-01 | 1985-03-12 | Georges Van Daele | N-(3-hydroxy-4-piperidinyl)benzamide derivatives |
| US5114715A (en) * | 1990-11-29 | 1992-05-19 | Sepracor Inc. | Methods of use and compositions of (s)-isoflurane and (s)-desflurane |
| US5114714A (en) * | 1990-11-29 | 1992-05-19 | Sepracor, Inc. | Methods of use and compositions of (r)-isoflurane and (r)-desflurane |
| EP0649307A4 (en) * | 1992-07-07 | 1996-06-26 | Sepracor Inc | METHOD FOR USING (-) - CISAPRIDE FOR TREATING GASTIC EYE ELEMENTS AND OTHER DISEASES. |
| EP1170010A3 (en) * | 1992-07-07 | 2004-05-19 | Sepracor Inc. | Method of using (+) cisapride for the treatment of gastro-esophageal reflux disease and other disorders |
| WO1995001803A1 (en) * | 1993-07-06 | 1995-01-19 | Merck & Co., Inc. | H2 antagonist-gastrointestinal motility agent combinations |
| US5712293A (en) * | 1995-06-07 | 1998-01-27 | Sepracor, Inc. | Methods for treating gastro-esophageal reflux disease and other disorders associated with the digestive tract using optically pure (-) norcisapride |
| US5739151A (en) * | 1996-07-19 | 1998-04-14 | Sepracor Inc. | Method for treating emesis and central nervous system disorders using optically pure (+) norcisapride |
-
1996
- 1996-07-19 US US08/684,753 patent/US5739151A/en not_active Expired - Fee Related
-
1997
- 1997-07-02 CZ CZ19982508A patent/CZ293478B6/cs not_active IP Right Cessation
- 1997-07-02 HU HU9904360A patent/HUP9904360A3/hu unknown
- 1997-07-02 WO PCT/US1997/011629 patent/WO1998003173A1/en active IP Right Grant
- 1997-07-02 ES ES97932467T patent/ES2152687T3/es not_active Expired - Lifetime
- 1997-07-02 SK SK1239-98A patent/SK282673B6/sk unknown
- 1997-07-02 DE DE69703617T patent/DE69703617T2/de not_active Expired - Fee Related
- 1997-07-02 KR KR10-2001-7011625A patent/KR100422492B1/ko not_active IP Right Cessation
- 1997-07-02 KR KR10-2003-7013889A patent/KR100533237B1/ko not_active IP Right Cessation
- 1997-07-02 DK DK97932467T patent/DK0896539T3/da active
- 1997-07-02 KR KR10-2001-7011626A patent/KR100399808B1/ko not_active IP Right Cessation
- 1997-07-02 AT AT97932467T patent/ATE197762T1/de not_active IP Right Cessation
- 1997-07-02 PT PT97932467T patent/PT896539E/pt unknown
- 1997-07-02 CA CA002245768A patent/CA2245768C/en not_active Expired - Fee Related
- 1997-07-02 JP JP10506954A patent/JP3097697B2/ja not_active Expired - Fee Related
- 1997-07-02 NZ NZ331291A patent/NZ331291A/en unknown
- 1997-07-02 BR BR9708287-2A patent/BR9708287A/pt not_active Application Discontinuation
- 1997-07-02 AU AU35920/97A patent/AU3592097A/en not_active Abandoned
- 1997-07-02 KR KR1019980706152A patent/KR100328731B1/ko not_active IP Right Cessation
- 1997-07-02 IL IL12570397A patent/IL125703A0/xx unknown
- 1997-07-02 TR TR1998/01816T patent/TR199801816T2/xx unknown
- 1997-07-02 CN CN97192157A patent/CN1215992A/zh active Pending
- 1997-07-02 EP EP97932467A patent/EP0896539B1/en not_active Expired - Lifetime
- 1997-07-02 PL PL97335254A patent/PL189610B1/pl not_active IP Right Cessation
- 1997-08-05 US US08/905,941 patent/US5877188A/en not_active Expired - Fee Related
-
1998
- 1998-07-13 US US09/114,319 patent/US6114356A/en not_active Expired - Fee Related
- 1998-08-07 NO NO19983636A patent/NO317178B1/no unknown
- 1998-08-10 IS IS4820A patent/IS4820A/is unknown
- 1998-09-09 BG BG102757A patent/BG63190B1/bg unknown
-
2001
- 2001-02-22 GR GR20010400294T patent/GR3035460T3/el not_active IP Right Cessation
-
2004
- 2004-03-19 NO NO20041166A patent/NO20041166L/no not_active Application Discontinuation
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR9708287A (pt) | Processo para tratar ou prevenir um distúrbio do sistema nervoso central em um ser humano, para eliciar um efeito antiemético em um ser humano e para tratar um estado de doença em um ser humano, composição farmacêutica para tratar de distúrbios do sistema nervoso central em um ser humano, e, forma de dosagem unitária farmacêutica | |
| DK0597033T3 (da) | IGF-1 til forbedring af den neurale tilstand | |
| BR9911161A (pt) | Processos para o tratamento de um volume particular de tecido de planta ou animal, para produção de pelo menos um agente fotoativado em um volume particular de material, para o tratamento médico de um volume particular de tecido, e, aparelhos para o tratamento de um volume particular de tecido de planta ou animal e, para administração de um tratamento médico fotodinâmico. | |
| DE60134453D1 (de) | Pharmazeutische Zusammensetzungen zur Behandlung von ZNS und anderen Krankheiten | |
| DE60126980D1 (de) | Therapeutische agentien und methoden ihrer verwendung zur behandlung von amyloidogenen erkrankungen | |
| DE60216830D1 (de) | Pharmazeutische Zusammensetzungen zur Behandlung von Störungen des ZNS oder anderen Erkrankungen | |
| ATE209908T1 (de) | RADIKALFÄNGER (ßSPIN TRAPSß) ZUR BEHANDLUNG VON MIT OXIDATION VON LIPIDEN UND PROTEINEN VERBUNDENEN ERKRANKUNGEN | |
| DE69840495D1 (de) | Darreichungsform, welche rasche dispersionseigenschaften entfaltet, anwendungsverfahren sowie verfahren zur herstellung derselben | |
| ATE399553T1 (de) | Pharmazeutische zusammensetzungen mit dextromethorphan und chinidin zur behandlung von neurologischen erkrankungen | |
| BR0012488A (pt) | Composição farmacêutica, métodos para melhorar a taxa de absorção de um ou mais do que um agente farmaceuticamente ativo em mamìferos, para melhorar o inìcio do benefìcio terapêutico de um ou mais do que um agente farmaceuticamente ativo em mamìferos, para inibição de gastroirritação em um mamìfero, e para tratamento de mamìferos necessitando do tratamento proporcionado por um ou mais do que um agente farmaceuticamente ativo, e, processo para preparar uma composição farmacêutica | |
| EP0740650A4 (en) | CO-MEDICINAL PRODUCTS USED AS A REGULATED MEDICINE DELIVERY PROCESS | |
| MY111260A (en) | Pharmaceutical composition for the treatment of nicotine dependence | |
| PT95868A (pt) | Processo para a prparacao de uma composicao de libertacao retardada que compreende acido polipropenoico e um medicamento activo, para tratamento de doencas periodonticas | |
| EP0934748A3 (en) | Von Willenbrand factor (vWF)- containing preparation, process for preparing vWF-containing preparations, and use of such preparations | |
| BR9813318A (pt) | Processo de tratamento de tumores e degeneração macular em paciente humano ou veterinário, composição farmacêutica para tratamento de tumores e degeneração macular em um paciente humano ou veterinário | |
| UA60352C2 (uk) | Синтетичні полісахариди та фармацевтична композиція, що їх містить | |
| PE2096A1 (es) | Metodos y composiciones para tratar la periodontitis adulta | |
| BR9912581A (pt) | Processos para tratar ou prevenir um distúrbio causado por disfunção da motilidade gastrointestinal em um humano e para elicitar um efeito procinético em um humano, e, composição farmacêutica | |
| ATE4115T1 (de) | 6-substituierte 11-alkylen-morphantridine, verfahren zu ihrer herstellung und diese enthaltende therapeutische mittel. | |
| BR9808114A (pt) | Formulação de ração para cavalos utilizável para tratar epm, processos para tratar pm em um cavalo que necessita deste tratamento, para prevenir infecção com s. neutrona em cavalos, e, para exterminar s. neurona em cavalos | |
| ATE321553T1 (de) | Arzneimittel für hinterstrangataxie und zusammensetzung zur behandlung von hinterstrangataxie | |
| BR9808063A (pt) | Métodos para tratamento de distúrbios vasculares. | |
| DE3878154D1 (de) | Oral anzuwendende arzneiform zur einmal taeglichen behandlung der hypertonie mit diltiazemhydrochlorid. | |
| DE69009765D1 (de) | Kynurensäurederivate, deren herstellung und diese enthaltende pharmazeutische zusammensetzungen. | |
| DE60004093D1 (de) | Pharmazeutische zusammensetzung welche riluzol und gabapentin enthält zur behandung von motoneuronalen krankheiten |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
| B09B | Patent application refused [chapter 9.2 patent gazette] |
Free format text: INDEFIRO O PRESENTE PEDIDO DE PATENTE DE ACORDO COM ART. 36 DA LPI |